Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. Januar 2018 16:01 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018

CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
23. Januar 2018 16:01 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of common stock,...
18. Januar 2018 20:43 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Announces Pricing of $475 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 7,089,553 shares of common stock...
17. Januar 2018 16:01 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Announces Proposed Offering of Common Stock

CAMBRIDGE, Mass., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $400 million...
08. Januar 2018 07:01 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value

- Ivosidenib NDA for IDH1m R/R AML Submitted in December for Priority Review; Multiple Pivotal Trials Ongoing or Planned for Ivosidenib in Frontline AML and Solid Tumors Including 4Q 2018 Initiation...
02. Januar 2018 07:30 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018

CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
26. Dezember 2017 07:30 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation

- Ivosidenib Has Potential to be a First-in-Class Therapy for Patients with R/R AML and an IDH1 mutation - - Company Also Announces FDA Clearance of Investigational New Drug Application (IND) for...
11. Dezember 2017 16:05 ET | Quelle: Agios Pharmaceuticals, Inc.

Data from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation

- Ivosidenib and Enasidenib Evaluated in Combination with Standard Induction (7+3) Chemotherapy or Azacitadine in Newly Diagnosed Patients From Two Phase 1 Studies - - Phase 3 Trial of Ivosidenib or...
11. Dezember 2017 16:00 ET | Quelle: Agios Pharmaceuticals, Inc.

New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML

- First Expansion Data and Updated Dose-Escalation Data Support NDA Submission for IDH1m R/R AML by Year End 2017 and Demonstrate Overall Efficacy and Safety Profile Consistent with Previously...
10. Dezember 2017 18:00 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency

– Safety and Efficacy Profile Consistent with Previously Reported Data – – Hemoglobin Increases >1.0 g/dL in 26 of 52 Patients Overall; Responses Remain Durable with Completion of Six Month Core...

Vorherige Seite